Broad reactivity of HLA-E restricted TCRs highlights challenges in universal T cell therapy development 2335164
Chelston Ang, Simon Ellington, Ruhi Roy, María Abad-Fernández et autres
Abstract Introduction T cell receptor—engineered therapies (TCR-Ts) redirect T cells to tumor antigens presented by human leukocyte antigen (HLA) molecules but are limited by the extreme polymorphism of classical HLAs, restricting broad applicability. HLA-E is a non-classical, functionally monomorphic HLA molecule that …
us, es (code pays fourni par la source)
0 citations
The Journal of Immunology